drugset
drugset / Trial / NCT00374049

MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer

NCT00374049 ↗

Phase 1 Completed 14 enrolled Olivera Finn Oncovir, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also known as HiltonolTM, in boosting the body's immune system's response to an experimental vaccine therapy (called the MUC-1 vaccine).

Timeline

Start
2006-06
Primary completion
2008-01
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Hiltonol Other / unclassified 25 ug/kg Intramuscular
Subject Hiltonol Other / unclassified 50 ug/kg Intramuscular
Subject MUC1 Vaccine 100 ug Subcutaneous
Background sargramostim Protein / enzyme biologic 100 ug Subcutaneous

Indications

prostate cancer